{"id":391090,"date":"2016-08-04T00:00:00","date_gmt":"2016-08-04T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnecg0004-2016-biopharma-multiple-sclerosis-unmet-need-relapsing-remitting-multiple-sclerosis-us-eu-2016\/"},"modified":"2026-05-12T11:40:57","modified_gmt":"2026-05-12T11:40:57","slug":"unnecg0004-2016-biopharma-multiple-sclerosis-unmet-need-relapsing-remitting-multiple-sclerosis-us-eu-2016","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnecg0004-2016-biopharma-multiple-sclerosis-unmet-need-relapsing-remitting-multiple-sclerosis-us-eu-2016\/","title":{"rendered":"Multiple Sclerosis | Unmet Need | Relapsing Remitting Multiple Sclerosis | US\/EU | 2016"},"content":{"rendered":"<p>An increasing number of clinically unique disease-modifying therapies (DMTs) have been approved for the treatment of relapsing-remitting multiple sclerosis (RR-MS), the most prevalent form of MS. Nevertheless, all approved drugs present clinical shortcomings, and opportunity lingers for a DMT that can present an even more-favorable balance of potent and low risk. Meanwhile, the development of neuroprotective and remyelinating strategies remains a critical goal. This Unmet Need content provides quantitative insight into U.S. and European physicians\u2019 perceptions of key treatment drivers and goals in the treatment of RR-MS, and the current level of unmet need in this area. We analyze the commercial opportunities and how emerging therapies may capitalize on these opportunities.<\/p>\n","protected":false},"template":"","class_list":["post-391090","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-multiple-sclerosis","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-858"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391090","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391090\/revisions"}],"predecessor-version":[{"id":394213,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391090\/revisions\/394213"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391090"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}